Perrigo Company plc Deferred Tax Asset, Interest Carryforward
Perrigo Company plc (PRGO) had Deferred Tax Asset, Interest Carryforward of $131.30 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetInterestCarryforward · last filed 2026-02-26
- 2025-12-31: Deferred Tax Asset, Interest Carryforward $131.30M.
- 2024-12-31: Deferred Tax Asset, Interest Carryforward $119.10M; Deferred Tax Asset, Interest Carryforward as first filed $88.40M.
- 2023-12-31: Deferred Tax Asset, Interest Carryforward $50.80M.
| Period end | Deferred Tax Asset, Interest Carryforward | Deferred Tax Asset, Interest Carryforward as first filed |
|---|---|---|
| 2025-12-31 | $131.30M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $119.10M 10-K · filed 2026-02-26 | $88.40M 10-K · filed 2025-02-28 |
| 2023-12-31 | $50.80M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |